NX-1607 is being evaluated in multiple immuno-oncology indications, including a range of solid tumor types
Phase 1 clinical trial now enrolling patients in U.K. with plans to expand to clinical sites in the U.S.
https://finance.yahoo.com/news/nurix-therapeutics-announces-clearance-investigational-120000588.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.